Adicet Bio, Inc. (ACET)
NASDAQ: ACET · Real-Time Price · USD
0.6706
-0.0150 (-2.19%)
At close: Aug 1, 2025, 4:00 PM
0.7030
+0.0324 (4.83%)
After-hours: Aug 1, 2025, 7:43 PM EDT

Company Description

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States.

It offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients.

The company’s lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the potential treatment of autoimmune diseases and relapsed/refractory B-cell non-hodgkin’s lymphoma.

It also develops ADI-270, an armored gamma delta CAR T cell product candidate to treat multiple CD70+ solid tumor and hematological malignancies indications, with renal cell carcinoma.

The company was founded in 2014 and is based in Boston, Massachusetts.

Adicet Bio, Inc.
Adicet Bio logo
CountryUnited States
Founded1947
IndustryBiotechnology
SectorHealthcare
Employees152
CEOChen Schor

Contact Details

Address:
131 Dartmouth Street, 3rd Floor
Boston, Massachusetts 02116
United States
Phone650 503 9095
Websiteadicetbio.com

Stock Details

Ticker SymbolACET
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0000002034
CUSIP Number007002108
ISIN NumberUS0070021086
Employer ID11-1720520
SIC Code5122

Key Executives

NamePosition
Chen Schor BA, CPA, M.B.A.Chief Executive Officer, President and Director
Brian Nicholas HarveyChief Financial Officer
Dr. Blake Aftab Ph.D.Senior Vice President and Chief Scientific Officer
Dr. Donald Healey Ph.D.Chief Technology Officer
Amy LockeChief Human Resource Officer
Dr. Julie Maltzman M.D.Chief Medical Officer

Latest SEC Filings

DateTypeTitle
Oct 1, 201915-12GSecurities registration termination
Oct 1, 2019S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
Oct 1, 2019S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
Oct 1, 2019S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
Oct 1, 2019S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
Oct 1, 2019S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
Oct 1, 2019S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
Oct 1, 20198-KCurrent Report
Sep 20, 20198-KCurrent Report
Aug 26, 20198-KCurrent Report